SOLAR-PROMOTION
15.5.2024 15:14:34 CEST | Business Wire | Press release
Climate-neutral power generation from solar and wind will place several new challenges on the energy system. Key is that a significantly higher degree of flexibility will be required compared to today to keep supply and consumption in balance. Flexible consumers can make a significant contribution to this. How this can be achieved will be an important topic at EM-Power Europe, the international trade fair for energy management and integrated energy solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515343343/en/
EM-Power Europe 2024 presents a wide range of solutions for more digitalization and flexibility. (Photo: Solar Promotion GmbH)
"According to EU calculations, the demand for flexibility will increase by 133 percent between now and 2030," explains Michael Villa, Managing Director of the European industry association smartEn. In a recent study, Agora Energiewende came to the conclusion that by 2035, electric cars, heat pumps and home storage systems will be able to shift around ten percent of the annual electricity demand required in Germany. That would accumulate to around 100 terawatt hours. This flexibility on the consumer side will save the economy around 4.8 billion euros. But how can consumers make contributions to the energy transition?
Making ideal use of your own electricity
An initial consumer contribution to flexibilization has been a proven state of the art for years: prosumers with their own photovoltaic system linked to a stationary battery storage system, their own heat pump and charge their electric car with the electricity they generate themselves. This way, they not only minimize their own electricity consumption from the grid - they also reduce the load on the respective distribution grid by maximizing their own consumption.
Supply and demand
When there is a lot of electricity available from the sun and wind, prices on the European trading platform EEX fall. From 2025, all electricity suppliers in Germany will be obliged to offer their customers dynamic tariffs. They will then be able to optimize their consumption in terms of price. However, if many households consume a lot of electricity at the same time, the distribution grids will be under considerable strain. Making grid charges more flexible could counteract this effect: from 2025, grid charges in Germany will be higher at times of high grid utilization and lower at times of low utilization.
Suppliers intervene
Suppliers will also contribute to flexibility to a greater extent: if grid capacity threatens to become scarce, they can reduce their customers' consumption. This is an example that has been successfully practiced: If a bottleneck becomes apparent, suppliers can temporarily switch off connected heat pumps themselves. However, customers do not suffer any loss of comfort as a result, as thermal storage units keep their homes warm. In return, they receive the electricity for their heat pump at a particularly favorable price.
New: throttling instead of switching off
A novelty to the Energy Industry Act (EnWG) allows grid operators to throttle some wallboxes and heat pumps if there is a risk of grid overload. In return, grid operators may no longer refuse to connect such consumers on the grounds of possible grid overload.
EM-Power Europe
EM-Power Europe is the international trade fair for energy management and integrated energy solutions. Under the motto "Empowering Grids and Prosumers", it brings together stakeholders and focuses on current trends and developments. EM-Power Europe will take place from June 19 to 21, 2024 at Messe München.
Further information: www.em-power.eu
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515343343/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
